Abbott Laboratories Corporation

Abbvie Inc.

Galapagos Nv

Abbvie S.a.r.l.

Abbvie Overseas Sarl

Abbvie Global Enterprises Ltd.

John R Koenig

Chih-hung Lee

Arthur Gomtsyan

Erol K Bayburt

Robert G Schmidt

Brian S Brown

Richard J Perner

Marc J Scanio

Robert J Altenbach

Guo Zhu Zheng

Bo Liu

Andrew Bogdan

Philip R Kym

Marlon D Cowart

Sean Colm Turner

Stanley DiDomenico

Tammie K White

Jerome F Daanen

Ming Clinton Yeung

Irene I Drizin

Xenia Beebe Searle

Margaret Chi-Ping Hsu

Xueqing Wang

Tammie K Jinkerson

Stephen N Greszler

Gregory A Gfesser

David A DeGoey

Michael E Kort

Huaqing Liu

Kirill A Lukin

Eric A Voight

Mark A Matulenko

Russell Drew Cink

Gilles Chambournier

Brian D Wakefield

Lawrence A Black

Anil Vasudevan

Meena V Patel

Karine Fabienne Malagu

Nicolas Desroy

Derek W Nelson

Sachin V Patel

Steven P Latshaw

Marvin Robert Leanna

Dilinie P Fernando

Gang Zhao

Hillary M Peltier

Chih-Hung Lee

Chen Zhao

Clara I Villamil

Andrew O Stewart

Jennifer M Frost

William H Bunnelle

Kevin R Woller

Lei Shi

Kennan C Marsh

Vincent S Chan

Kathy A Sarris

Shashank Shekhar

Kerren Kalai Swinger

Christopher Gaëtan Housseman

Timothy A Grieme

Béranger Duthion

Bruce Clapham

Robert M Leanna

Sylvain Couty

Elsa De Lemos

Daniel P Larson

Weili Wang

Steve Latshaw

Ana Aguirre

William Ramesh Esmieu

Xeuquing Wang

Arthur R Gomtsyan

Stanley Didomenico

Margaret Hsu

Dilini Fernando

Russel D Cink

The invention discloses compounds of Formula (I) wherein R, R, R, R, R, R, and Rare as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.

Substituted pyrrolidines and methods of use

The present invention provides for compounds of formula (I) wherein R, m, Z, G, R, and Rhave any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sj&#xf6;gren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

Modulators of cystic fibrosis transmembrane conductance regulator protein

The invention discloses compounds of Formula (I) wherein R, R, R, R, R, R, R, and Rare as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.

Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R, R, and Rare as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by voltage-gated sodium channels, e.g., Na1.7 and/or Na1.8. Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.

6-heteroaryloxy- or 6-aryloxy-quinoline-2-carboxamides and method of use

The present invention provides for compounds of formula (I) wherein X, Y, and Rhave any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sj&#xf6;gren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

Substituted tricyclics and method of use

Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein A, Rand Rare as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by voltage-gated sodium channels, e.g., Na1.7 and/or Na1.8. Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.

Indazole ureas and method of use

Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R, Z, Z, and n are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by Tropomysin receptor kinases (Trk). Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.

Furo-3-carboxamide derivatives and methods of use

The invention provides for compounds of formula (I) wherein R, X, Y, R, R, R, R, R, R, R, R, R, R, R, m, and R&#x2033; have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sj&#xf6;gren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

Substituted chromanes and method of use

The present invention is directed to compounds of formula (I) wherein variables X, X, Y, R, R, R, R, A, A, A, and Aare as defined in the description, and methods of use to treat pain, neuropathic pain, allodynia, pain associated with inflammation or an inflammatory disease, inflammatory hyperalgesia, bladder overactivity, and urinary incontinence.

Antagonists of the vanilloid receptor subtype 1 (VR1) and uses thereof

The present invention discloses novel compounds of general formula (I) or a pharmaceutically acceptable salt or prodrug thereof (in which X-X, R-R, Z-Zand Arare defined herein), a method for inhibiting the VR1 receptor in mammals using these compounds, a method for controlling pain in mammals, and pharmaceutical compositions including those compounds and a process for making those compounds.

Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor

Compounds that are antagonists of the VR1 receptor, having formula (I) or a pharmaceutically acceptable salt, prodrug, or salt of a prodrug thereof, wherein A, A, A, A, R, R, R, X, Y, Z, L, n, and m, are as defined herein, and are useful in disorders prevented or ameliorated by inhibiting the VR1 receptor.

Tetrahydroquinolinyl compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof

Macrocyclic pyrimidine compounds, compositions comprising such compounds, methods for making the compounds, and methods of treating and preventing the progression of diseases, conditions, and disorders using such compounds and compositions are described herein.

Macrocyclic pyrimidine derivatives

Macrocyclic Spiro pyrimidine compounds of formula (I): compositions comprising such compounds, methods for making the compounds, and methods of treating and preventing the progression of diseases, conditions, and disorders using such compounds and compositions are described herein.

Macrocyclic spiro pyrimidine derivatives

Compounds of formula (I) are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity, wherein X, X, X, X, X, R, R, R, R, R, R, Z, Zand L are as defined in the description.

Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor

Growing community of inventors

Chicago, IL, United States of America

John R Koenig